Novo Ventures invests millions in Zealand competitor after initiative organized by Zealand co-founder

Novo Ventures is one of the group of investors who are investing DKK 235 million (USD 34.9 million) in the newly-founded spinout company Vectivbio, which will develop a drug for short bowel syndrome. The person behind the investment is Zealand co-founder Jørgen Søborg Petersen.

Naveed Siddiqi is a partner at Novo Ventures and responsible for the fund's investment in Zealand competitor Vectivbio. Photo: Novo Holdings/ PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles